Institute for Wealth Management LLC. Buys 11,965 Shares of Sanofi SA (NYSE:SNY)

Share on StockTwits

Institute for Wealth Management LLC. increased its stake in shares of Sanofi SA (NYSE:SNY) by 160.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 19,414 shares of the company’s stock after purchasing an additional 11,965 shares during the quarter. Institute for Wealth Management LLC.’s holdings in Sanofi were worth $840,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SNY. Lazard Asset Management LLC increased its position in shares of Sanofi by 47,594.3% during the 1st quarter. Lazard Asset Management LLC now owns 2,384,716 shares of the company’s stock valued at $105,595,000 after purchasing an additional 2,379,716 shares during the last quarter. Schafer Cullen Capital Management Inc grew its position in Sanofi by 106.8% in the 2nd quarter. Schafer Cullen Capital Management Inc now owns 728,871 shares of the company’s stock valued at $30,088,000 after acquiring an additional 376,410 shares during the last quarter. Fisher Asset Management LLC grew its position in Sanofi by 2.2% in the 2nd quarter. Fisher Asset Management LLC now owns 16,868,423 shares of the company’s stock valued at $729,897,000 after acquiring an additional 367,961 shares during the last quarter. Richard C. Young & CO. LTD. bought a new position in Sanofi in the 1st quarter valued at $8,583,000. Finally, FMR LLC grew its position in Sanofi by 1.9% in the 1st quarter. FMR LLC now owns 9,233,558 shares of the company’s stock valued at $408,862,000 after acquiring an additional 175,580 shares during the last quarter. 7.04% of the stock is currently owned by hedge funds and other institutional investors.

In other news, major shareholder Sanofi bought 93,750 shares of the stock in a transaction on Monday, July 22nd. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $1,500,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 1.00% of the stock is currently owned by corporate insiders.

SNY has been the topic of several research analyst reports. TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a research report on Friday, June 21st. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research report on Tuesday, August 6th. Finally, UBS Group raised Sanofi from a “neutral” rating to a “buy” rating in a research report on Wednesday, August 14th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Sanofi has an average rating of “Hold” and a consensus price target of $51.00.

Sanofi stock traded up $0.82 during mid-day trading on Monday, hitting $42.84. The company’s stock had a trading volume of 44,808 shares, compared to its average volume of 1,239,559. The company has a 50 day moving average of $42.20 and a 200-day moving average of $42.61. The stock has a market cap of $104.90 billion, a PE ratio of 13.64, a P/E/G ratio of 2.41 and a beta of 0.67. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. Sanofi SA has a one year low of $40.00 and a one year high of $45.62.

Sanofi (NYSE:SNY) last announced its quarterly earnings data on Monday, July 29th. The company reported $0.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.07. The company had revenue of $8.63 billion for the quarter, compared to the consensus estimate of $8.42 billion. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. Sanofi’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.25 EPS. On average, equities research analysts forecast that Sanofi SA will post 3.1 EPS for the current fiscal year.

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Story: What does an inverted yield curve signify?

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CSat Investment Advisory L.P. Purchases 776 Shares of Alphabet Inc
CSat Investment Advisory L.P. Purchases 776 Shares of Alphabet Inc
CSat Investment Advisory L.P. Purchases 867 Shares of JD.Com Inc
CSat Investment Advisory L.P. Purchases 867 Shares of JD.Com Inc
CSat Investment Advisory L.P. Boosts Stake in Alphabet Inc
CSat Investment Advisory L.P. Boosts Stake in Alphabet Inc
CSat Investment Advisory L.P. Buys 151,552 Shares of Overstock.com Inc
CSat Investment Advisory L.P. Buys 151,552 Shares of Overstock.com Inc
Square, Inc.  Stake Raised by CSat Investment Advisory L.P.
Square, Inc. Stake Raised by CSat Investment Advisory L.P.
Jane Street Group LLC Boosts Stock Holdings in Aaron’s, Inc.
Jane Street Group LLC Boosts Stock Holdings in Aaron’s, Inc.


© 2006-2019 Ticker Report